Navigation Links
PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
Date:5/21/2008

. In Phase 1 clinical trials, PTC124 was generally well tolerated, achieved target plasma concentrations that have been associated with activity in preclinical models and did not induce ribosomal read through of normal stop codons. PTC124 has demonstrated pharmacodynamic proof of concept in Phase 2a clinical trials in nonsense-mutation-mediated Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF).

About PTC Therapeutics Inc.

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary, small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally-discovered pipeline addresses multiple therapeutic areas, including genetic disorders, oncology and infectious diseases. In addition, PTC has developed proprietary technologies and extensive knowledge of post-transcriptional control processes that it applies in its drug discovery and development activities, including the Gene Expression Modulation by Small-molecules (GEMS) technology platform, which has been the basis for collaborations with leading pharmaceutical and biotechnology companies such as Pfizer, Celgene, CV Therapeutics and Schering-Plough. For more information, visit the company's website, http://www.ptcbio.com.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
2. PacificGMP Completes GMP Product Fill for Trius Therapeutics
3. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
4. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
5. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
6. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
7. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
8. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
11. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013   Life Line Screening ... services announced today the creation of a unique partnership ... MCM is a population health management ... growing list of clients. These important expanded services will ... conditions earlier. Effective prevention reduces cost of care when ...
(Date:5/22/2013)... , 22. Mai 2013  Grifols, ein ... Barcelona , Spanien, präsentierte ... eine höhere Dosis von PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) ... Alpha1-Antitrypsinmangel (AAT) auf ein Niveau anhebt, das ... Bereichs liegt. ATT-Mangel ist eine lebensbedrohliche, genetische ...
(Date:5/22/2013)... CITY , May 22, 2013 ... today announced it received 510(k) clearance from the ... diagnostic X-ray image processing workstation that combines radio ... one platform.  Varian,s Nexus DRF Digital X-Ray Imaging ... variety of image receptors, including CCD cameras and ...
Breaking Medicine Technology:Life Line Screening and MCM Solutions for Better Health Announce New Partnership 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Varian Medical Systems Receives FDA 510(k) Clearance of its Nexus DRF Digital X-Ray Imaging System 2
... In a randomized, double-blind, placebo-controlled trial of 247 patients who ... and liver enzymes; however, vitamin E was more successful for ... associated with fatty liver disease, insulin resistance, and obesity, and ... have NASH. The disease progresses to inflammation in the liver ...
... (Nasdaq: GPRO ) announced today that the Company will ... York on November 3, 2009 at approximately 2:10 p.m. Eastern ... Conference in New York on November 18, 2009 at approximately ... be webcast live and may be accessed through a link ...
Cached Medicine Technology:Vitamin E Improves NASH 2Gen-Probe to Webcast Two Upcoming Investor Presentations 2
(Date:5/22/2013)... New York (PRWEB) May 22, 2013 Jury ... nation’s first trial involving a da Vinci lawsuit, ... case, the family of a man who allegedly died of ... more than $8 million in damages from Intuitive Surgical, Inc. ... its physician training program for the da Vinci Surgical System ...
(Date:5/22/2013)... Reporter , , WEDNESDAY, May 22 (HealthDay News) -- Anyone ... is something about feet that fungi seem to like. ... the fungal groups that live on your skin -- ... It,s no secret that the human body is ... fungi, both outside and inside. And it,s mainly a ...
(Date:5/22/2013)... New York, New York (PRWEB) May 22, 2013 ... a metal-on-metal version of the DePuy Pinnacle Hip Replacement ... underway in Texas Federal Court, Bernstein Liebhard LLP reports. ... Court has directed DePuy Orthopaedics to produce monitoring reports ... government into the company’s medical device marketing practices. ...
(Date:5/22/2013)... Today, Zane Benefits, Inc. published a new ... Zane Benefits, which provides comprehensive and flexible alternatives to ... defined contribution plans and health reimbursement ... in 2014 as part of the Affordable Care Act ... will become available through new state health insurance exchanges. ...
(Date:5/22/2013)... may be reaping enormous income for patients whose ... contracted in their intensive care units. , In ... American Journal of Medical Quality , the ... an avoidable central line-associated bloodstream infection (CLABSI) costs ... a similar infection-free patient. Moreover, hospitals earn nearly ...
Breaking Medicine News(10 mins):Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 2Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 3Health News:Da Vinci Robot Lawsuits: Bernstein Liebhard LLP Notes Beginning of Jury Deliberations in Nation’s First Trial Involving Alleged Da Vinci Surgery Complications 4Health News:Scientists Map the Fungi on Your Feet 2Health News:Scientists Map the Fungi on Your Feet 3Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation 2Health News:DePuy Pinnacle Lawsuit News: Bernstein Liebhard LLP Notes New Order in Federal Pinnacle Litigation Requiring Production of Monitoring Reports from Federal Investigation 3Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 3Health News:Hospitals profit when patients develop bloodstream infections 2Health News:Hospitals profit when patients develop bloodstream infections 3Health News:Hospitals profit when patients develop bloodstream infections 4
... Daniel D. Von Hoff, Physician-in-Chief for the Translational Genomics Research ... Society of Clinical Oncology (ASCO) for his cancer research. ... A. Karnofsky Memorial Award and Lecture at ASCO,s 46th Annual ... ASCO will present the award to Dr. Von Hoff "for ...
... B for those with scent-robbing viral infection, study found ... help people who lose their sense of smell after ... study, 15 patients with post-viral olfactory dysfunction (PVOD) had ... patients were compared with PVOD patients treated with vitamin ...
... can be lost, treatment can work again , THURSDAY, April ... which certain tumor cells that become resistant to cancer drugs ... lead to new ways to combat drug resistance in cancer ... April 1 in the journal Cell . , Although ...
... medicine specialists), subspecialists, medical students, and allied health ... Medicine 2010, the annual scientific meeting of the ... 24 (Thursday - Saturday), at the Toronto Convention ... devoted to adult medicine and is the second-largest ...
... promise for safely removing large brain tumors from an ... sinus cavities, clinical researchers at the Brain Tumor Center ... University Hospital have found. The findings, to be ... Journal of Neurosurgery and previously published online in ...
... of elderly patients. In many cases, a hip fracture is ... health, setting off a long list of potential complications. ... issue of The Journal of Bone and Joint Surgery ... by the American Society of Anesthesiologists (ASA)-is a leading indicator ...
Cached Medicine News:Health News:TGen Physician-In-Chief Dr. Daniel D. Von Hoff wins ASCO award 2Health News:Study Suggests How Some Cancers Resist Treatment 2Health News:Study Suggests How Some Cancers Resist Treatment 3Health News:All you need to know about adult medicine is at Internal Medicine 2010 2Health News:All you need to know about adult medicine is at Internal Medicine 2010 3Health News:All you need to know about adult medicine is at Internal Medicine 2010 4Health News:All you need to know about adult medicine is at Internal Medicine 2010 5Health News:All you need to know about adult medicine is at Internal Medicine 2010 6Health News:Researchers quantify benefits of minimally invasive removal of hard-to-reach tumors 2Health News:Researchers quantify benefits of minimally invasive removal of hard-to-reach tumors 3Health News:Hip surgery success partially predicted by number of other existing conditions 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: